Update on glial antibody-mediated optic neuritis.
Update on glial antibody-mediated optic neuritis.
复制标题
神经胶质抗体介导的视神经炎的最新进展。
DOI：
10.1007/s10384-022-00932-1
复制
发表时间：
2022
影响因子：
2.4
通讯作者：
Shihui Wei
中科院分区：
文献类型：
--
作者：
Honglu Song;Huanfen Zhou;Shihui Wei
视神经炎（ON）是指视神经的炎性脱髓鞘病变，其可引起急性或亚急性视力丧失，并且是年轻成人视力丧失的主要原因。我们对典型ON的大部分理解来自视神经炎治疗试验。抗水通道蛋白-4免疫球蛋白的胶质细胞自身抗体神经胶质细胞抗体（AQP 4-IgG）和髓鞘少突胶质细胞糖蛋白免疫球蛋白（MOG-IgG）是近年来建立的神经胶质瘤的生物标志物，它们的检测对非典型神经胶质瘤的诊断、治疗、不同类型ON患者的随访结果。AQP 4-IgG和MOG-建议对非典型ON患者进行IgG筛查，对NMOSD和MOGAD发病机制的研究将促进靶向免疫治疗的开发和上市。新的和有效的药物的应用，如选择性补体C5抑制剂、IL-6受体抑制剂、B细胞耗竭剂和针对其他单克隆抗体的药物，提供了额外的医学证据。本文综述了胶质抗体介导的ON的诊断和治疗。
Optic neuritis (ON) refers to inflammatory demyelinating lesions of the optic nerve, which can cause acute or subacute vision loss and is a major cause of vision loss in young adults. Much of our understanding of typical ON is from the Optic Neuritis Treatment Trial. Glial autoantibodies to aquaporin-4 immunoglobulin (AQP4-IgG) and myelin oligodendrocyte glycoprotein immunoglobulin (MOG-IgG) are recently established biomarkers of ON that have revolutionized our understanding of atypical ON. The detection of glial antibodies is helpful in the diagnosis, treatment, and follow-up of patients with different types of ON. AQP4-IgG and MOG-IgG screening is strongly recommended for patients with atypical ON. Research on the pathogenesis of NMOSD and MOGAD will promote the development and marketing of targeted immunotherapies. The application of new and efficient drugs, such as the selective complement C5 inhibitor, IL-6 receptor inhibitor, B cell-depleting agents, and drugs against other monoclonal antibodies, provides additional medical evidence. This review provides information on the diagnosis and management of glial antibody-mediated ON.